L'intérêt à découvert pour Valneva donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Valneva. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Valneva (NASDAQ:VALN) Stock, Rapport sur les intérêts à découvert

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE

JMP Securities analyst Aaron Kimson maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Market Outperform and raises the price target from $179 to $200.

News

Price Target

Analyst Ratings

GWRE

JMP Securities Maintains Market Outperform on Guidewire Software, Raises Price Target to $200

Telsey Advisory Group analyst Dana Telsey maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Market Perform and maintains $26 price target.

Telsey Advisory Group Maintains Market Perform on Gap, Maintains $26 Price Target

A sudden single-day spike by Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has prompted traders to predict an upcoming bull run for <a href="https://www.benzinga.com/topic/meme-coins">the meme coin leaders.</a>
What Happened: With Dogecoin prices reflecting a relatively flat performance over the past week, an analyst who goes by &#8220;Kevin&#8221; on X, outlined his thoughts on the trajectory of Dogecoin. He stated that the meme coin is still trying to establish a successful bullish retest of its macro falling wedge, following its typical bull market correction of 60%.
After Friday&#8217;s price jump of 5%, Kevin further <a href="https://x.com/Kev_Capital_TA/status/1844725417569145294">predicted</a> that if this retest is successful, it could be the last opportunity to purchase Dogecoin at its current prices.
As Shiba Inu prices rally higher, crypto trader Javon Marks asked the crypto community, "Are you prepared for $0.000081?" He added that Shib has broken out of a recent falling wedge pattern and a much larger (unpictured) resisting trend.
He <a href="https://x.com/JavonTM1/status/1844779511864266898">predicts</a> a more than 342% rally from here, as this falling wedge will only help to &#8220;spark the process.&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41207040/dogecoin-killer-shiba-inu-up-39-over-the-past-30-days-but-that-will-accelerate-says-bullis">&#8216;Dogecoin Killer&#8217; Shiba Inu Up 39% Over The Past 30 Days But That &#8216;Will Accelerate,&#8217; Says Bullish Trader</a>
Why It Matters: Kevin's analysis suggests that Dogecoin is currently in a critical phase of its market cycle. If his prediction holds true, this could mean a significant uptick in the value of Dogecoin.
Meanwhile, Marks&#8217; prediction reflects a highly bullish run for Shiba Inu, which has already accumulated 34% over the past month. Shibburn data shows an increase of 83.4% in its burn rate over the past 24 hours as 4.6 million SHIB coins are thrown out of the ecosystem.
IntoTheBlock data shows that Doge and Shiba&#8217;s large transaction volume decreased by 23.8% and 35.5%, respectively. Daily active addresses for Dogecoin and Shiba Inu surged by 176.7% and 13.7%.
Dogecoin transactions greater than $100,000 increased from 227 to 251 in a single day, while Shiba Inu saw a marginal increase from 110 to 118. DOGE exchanges&#8217; net flows are down by 199%.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41209298/dogecoin-gearing-up-for-next-big-rally-this-is-the-price-traders-are-targeting">Dogecoin &#8216;Gearing Up For Next Big Rally&#8217;: This Is The Price Traders Are Targeting</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trading Ideas

$DOGE

$SHIB

What's Going On With Dogecoin, Shiba Inu Today?

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

Wedbush analyst Jay McCanless maintains Cavco Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) with a Outperform and raises the price target from $425 to $455.

CVCO

Wedbush Maintains Outperform on Cavco Indus, Raises Price Target to $455

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Market Perform and maintains $27.25 price target.

Telsey Advisory Group Maintains Market Perform on Albertsons Companies, Maintains $27.25 Price Target

ShiftPixy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NYSE">PIXY</a>) short percent of float has risen 64.94% since its last report. The company recently reported that it has 157 thousand shares sold short, which is 5.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ShiftPixy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670522_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ShiftPixy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ShiftPixy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ShiftPixy's peer group average for short interest as a percentage of float is 1.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PIXY

How Is The Market Feeling About ShiftPixy?

New Fortress Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NYSE">NFE</a>) short percent of float has fallen 39.61% since its last report. The company recently reported that it has 24.76 million shares sold short, which is 19.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.83 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>New Fortress Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670517_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for New Fortress Energy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing New Fortress Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, New Fortress Energy's peer group average for short interest as a percentage of float is 4.33%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(NFE) - Analyzing New Fortress Energy's Short Interest

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has fallen 25.0% since its last report. The company recently reported that it has 23.76 million shares sold short, which is 5.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728670512_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 4.90%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PATH

How Is The Market Feeling About UiPath?

EF Hutton analyst Jason Kolbert maintains Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Buy and maintains $23 price target.

MRNS

EF Hutton Maintains Buy on Marinus Pharma, Maintains $23 Price Target

Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) shares are trading higher on Friday. Warren Buffet&#8217;s Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) sold more of its shares in the bank, bringing its <a href="https://www.benzinga.com/markets/equities/24/10/41294370/warren-buffett-continues-trimming-bank-of-america-position-no-longer-needs-to-report-sales">stake below 10%</a>.
The Details: According to a Securities and Exchange Commission (SEC) filing, Berkshire Hathaway sold a total of 9.5 million Bank of America shares at an average price of $40.04 per share.
Berkshire made this move via three separate sales throughout the week with 3.9 million shares sold on Tuesday, 4 million shares sold on Wednesday and 1.6 million shares sold on Thursday.
Berkshire now holds a 9.98% stake in the bank which is equivalent to 775 million shares. Now that Berkshire Hathaway&#8217;s stake in Bank of America is below 10%, the company is no longer required to promptly report these transactions to the SEC.
Berkshire has been slowly selling off its Bank of America shares for quite some time now. Back in August, the company sold shares worth than <a href="https://www.benzinga.com/news/24/08/40471316/whats-going-on-with-bank-of-america-shares-tuesday">$550 million</a>. Berkshire also sold Bank of America Shares in September and July.
Bank of America is not the only bank to experience a selloff of its shares by Berkshire. Buffet&#8217;s Berkshire Hathaway has been unloading shares in companies across the banking industry for years. In 2022, Berkshire sold its remaining Wells Fargo shares. Furthermore, throughout 2020, Berkshire dumped its stake in JPMorgan Chase.
This could indicate that Buffet sees more value in stocks outside the banking industry. According to <a href="https://www.cnn.com/2021/02/16/investing/berkshire-hathaway-warren-buffett-stocks/index.html">CNN</a>, Berkshire bought stake in Verizon and Chevron after it sold its shares in JPMorgan Chase.
How To Buy Bank of America Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)'s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/markets/equities/24/10/41289653/tesla-stock-poised-to-pullback-to-1-month-low-whats-going-on">Tesla Stock Poised To Pullback To 1-Month Low: What&#8217;s Going On?</a>
BAC Price Action: At the time of writing, Bank of America stock is trading 4.94% higher at $41.95  per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>
Image: Image via Shutterstock

Movers

What's Going On With Bank Of America Stock Friday?

Wedbush analyst Seth Basham initiates coverage on Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Neutral rating and announces Price Target of $11.

Initiation

ARHS

Wedbush Initiates Coverage On Arhaus with Neutral Rating, Announces Price Target of $11

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic.
These new drugs, expected to hit the market by 2029, aim to surpass current efficacy levels while offering more convenient dosing options, such as oral and monthly injections. This shift, driven by innovation and competition, could change the market landscape despite Novo and Lilly&#8217;s current hold on the sector.
According to a <a target="_blank" href="https://assets.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt79266ca5d3a390c1/Obesity_Drug_Market_Report.pdf" rel="noreferrer noopener">report</a> by Morningstar, the global GLP-1 market is poised to reach $200 billion by 2031, with obesity treatment expected to account for 68% of sales.
While Novo Nordisk and Eli Lilly are projected to retain two-thirds of this market, driven by first-mover advantage and robust pipelines, new competitors could claim significant market share.
Public and private biopharma firms are increasingly focusing on cardiometabolic drug development, with 16 new obesity drugs potentially launching by 2029 the report added.
This pipeline includes candidates from major players such as <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">Roche Holdings AG</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and private companies like Boehringer Ingelheim.
Roche released topline results from the ongoing multi-part Phase 1 trial for CT-996, showing data better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>. Despite Novo Nordisk and Eli Lilly&#8217;s strong market positions, some analysts view their stocks as overvalued.
Achieving the market penetration needed to justify their current valuations would require near-unprecedented success, including capturing 75% of the U.S. obesity market and 95% of the global market by 2031.
Additionally, maintaining stable pricing seems unlikely, with increased competition and innovation expected to put downward pressure on drug prices.
Supply chain issues pose further challenges. Both companies face difficulties in manufacturing peptide-based drugs at scale, such as Wegovy and Zepbound.
While oral peptide drugs like high-dose Novo Nordisk&#8217;s Rybelsus and Viking Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37937068/viking-therapeutics-investigational-oral-obesity-drug-shows-reduced-weight-in-small-study" rel="noreferrer noopener">VK2735 offer alternatives</a>, they may be even harder to supply due to the higher doses required for efficacy.
Small molecule drugs, like Lilly&#8217;s orforglipron and Pfizer&#8217;s<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener"> danuglipron</a>, offer the best potential for scalable production, promising more streamlined manufacturing processes.
New entrants to the obesity drug market are pushing the envelope, with drug candidates from companies like Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), and Zealand Pharma (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDPF#OTC">ZLDPF</a>) on the horizon.
In a phase 1 study, Amgen&#8217;s AMG 133 showed an acceptable safety and tolerability profile and pronounced <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">dose-dependent weight loss</a>.&nbsp;
Altimmune said the body composition study of pemvidutide showed preservation of lean mass, with 25.5% of weight loss derived from lean mass and 74.5% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958653/why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday" rel="noreferrer noopener">from adipose tissue</a>.
These next-generation drugs could challenge the dominance of Novo and Lilly, especially if they offer better efficacy or fewer side effects.
However, Wegovy and Zepbound&#8217;s entrenched positions and ongoing innovation may keep Novo and Lilly at the forefront for the foreseeable future.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41295498/gsk-settles-majority-of-zantac-lawsuits-but-pipeline-doubts-remain" target="_blank" rel="noreferrer noopener">GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

General

AMGN

RHHBY

VKTX

ZLDPF

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names

CleanSpark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) shares are moving higher on Friday amid a rise in the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
The Details: Bitcoin is currently trading 3.4% higher at about $62,400 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>. Other crypto-linked stocks that are moving higher amid the rise in the price of Bitcoin include Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) and Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>).
What Else: Earlier this week, CleanSpark announced that it achieved 30 EH/s in operational hashrate. The company plans to achieve 37 EH/s by the end of the year and 50 EH/s in 2025.
CEO of CleanSpark Zach Bradford said, &#8220;We have added more operational hashrate than any other miner in 2024.&#8221;
In addition, the company announced that it promoted Brian Carson to Chief Accounting Officer from Director of Financial Reporting.
How To Buy CleanSpark Stock
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
CLSKFor example, in Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>)'s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/top-stories/24/10/41279865/elon-musk-may-unveil-teslas-robotaxi-but-consumers-respond-with-ehhh-new-study-reveals-skepticism-ne">Elon Musk May Unveil Tesla&#8217;s Robotaxi, But Consumers Respond With &#8216;Ehhh,&#8217; New Study Reveals Skepticism, Need For Trust-Building</a>
CLSK Price Action: At the time of writing, CleanSpark shares are trading 10.3% higher at $9.55, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Image via Shutterstock

$BTC

CLSK

COIN

RIOT

What's Going On With CleanSpark Shares Friday

Stephens &amp; Co. analyst Mike Scialla maintains Excelerate Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) with a Overweight and raises the price target from $21 to $28.

Stephens & Co. Maintains Overweight on Excelerate Energy, Raises Price Target to $28

RBC Capital analyst Kenneth Lee maintains Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Outperform and raises the price target from $500 to $535.

RBC Capital Maintains Outperform on Ameriprise Finl, Raises Price Target to $535

Barrington Research analyst Kevin Steinke maintains Crawford (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) with a Outperform and maintains $12 price target.

CRD/A

Barrington Research Maintains Outperform on Crawford, Maintains $12 Price Target

<a href="https://customers.microsoft.com/en-us/story/1772542324105866308-exelatech-azure-data-box-professional-services-en-india" title="https://customers.microsoft.com/en-us/story/1772542324105866308-exelatech-azure-data-box-professional-services-en-india">https://customers.microsoft.com/en-us/story/1772542324105866308-exelatech-azure-data-box-professional-services-en-india</a>

MSFT

XELA

Exela Technologies Partners With Microsoft Azure to Modernize Infrastructure, Enhance DocDNA Application, and Achieve High Availability, Scalability, and Efficiency Across Global Operations

Each week,&nbsp;Benzinga&#8217;s Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week of Oct. 11:
NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): The utility company saw headlines during the week related <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254312/hurricane-milton-descends-on-florida-analysts-warn-of-impact-on-disney-nexteras-flo">to Hurricane Milton</a> and power outages in the state of Florida, which likely increased interest from Benzinga readers. 
The company owns Florida Power &amp; Light, which has more than six million customers in Florida. A report said <a href="https://www.benzinga.com/news/24/10/41266095/hurricane-milton-knocks-out-power-for-over-2m-in-florida-nextera-energy-duke-energy-and-tampa-electr">over 900,000 lost power</a> after Hurricane Milton struck the state. While the power outages could have a short-term negative impact on the company, NextEra is also the owner of a renewable energy segment and should be able to recover from the hurricane impact over the long term.
The company is set to report third-quarter financial results on Oct. 23, which could provide more commentary on the storm's impact. The company has beaten analyst estimates for earnings per share in nine of the past 10 quarters and beaten revenue estimates in six of the past 10 quarters.
Shares were slightly up the past week, as seen on the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, and are up over 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204.png" alt="" class="wp-image-591824" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133206/Screenshot-204-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Monolithic Power Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): A chipmaker specializing in power management systems, Monolithic Power Systems continues to see elevated interest from Benzinga readers. 
The company appeared on the Stock Whisper Index<a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet"> two weeks ago</a> after Stifel increased its price target from $1,000 to $1,100 while maintaining a Buy rating.
The company is expected to report third-quarter financial results in October. The chipmaker has beaten analyst estimates for earnings per share in more than 10 straight quarters and beaten revenue estimates from analysts in six straight quarters. A strong earnings report could send shares higher.
Monolithic shares were up more than 2% on the week and are up over 57% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="496" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205.png" alt="" class="wp-image-591826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133227/Screenshot-205-768x384.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>): The software company and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) owner is no stranger to the Stock Whisper Index, making frequent appearances on the list thanks to growing interest in cryptocurrency and the company's strategy of buying Bitcoin with cash and by raising funds.
The company recently <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">announced the newest release</a> of MicroStrategy ONE, which includes integrations with Microsoft Teams and has new features for its AI bot. While many know the company as a major Bitcoin owner, MicroStrategy's software segment helps bring in cash flow to fuel the Bitcoin purchases.
MicroStrategy&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40857237/microstrategy-stock-climbs-after-bitcoin-purchase-heres-how-much-btc-michael-saylors-compa" target="_blank" rel="noreferrer noopener">recently announced it bought</a>&nbsp;$1.1 billion worth of Bitcoin bringing its total up to 244,800 Bitcoin. The company&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919378/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases" target="_blank" rel="noreferrer noopener">recently raised</a>&nbsp;over $800 million to redeem $500 million in senior secured notes and to buy additional Bitcoin.
MicroStrategy began buying Bitcoin in August 2020 and will continue to add more Bitcoin, as co-founder and Executive Chairman&nbsp;Michael Saylor&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/22/06/27865236/exclusive-michael-saylors-microstrategy-is-married-to-bitcoin-everything-else-in-the-world" target="_blank" rel="noreferrer noopener">previously told Benzinga.</a>
&#8220;We have a simple strategy and our strategy is we just acquire Bitcoin, and we hold the Bitcoin,&#8221; Saylor told Benzinga.
New leveraged and inverse ETFs targeting MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40930553/microstrategy-2x-leveraged-inverse-etfs-are-here-offer-unparalleled-access-to-microstrateg">also recently launched, </a>which could increase interest in the company.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206.png" alt="" class="wp-image-591827" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133249/Screenshot-206-768x385.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>): The natural gas company saw increased interest from Benzinga readers over the trading week. The surge in interest could be related to natural gas being volatile related to increased tension in the Middle East. 
Cheniere Energy will report third-quarter financial results on Oct. 31. The company has beaten analyst estimates for earnings per share in six of the past seven quarters and beaten revenue estimates from analysts in eight of the past 10 quarters.
Cheniere shares have traded near 52-week highs, as seen on the chart below. The stock is up 13% year-to-date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="498" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208.png" alt="" class="wp-image-591828" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133306/Screenshot-208-768x383.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): The scientific instruments and life sciences company saw a surge in interest from readers during the week. 
The increased attention could be related to Stephens <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41127566/industry-leader-thermo-fishers-contract-services-positioned-for-growth-amid-popular">initiating coverage on the stock </a>with an Overweight rating and $680 price target. The analyst sees the company benefiting from contract services and the surging demand for GLP-1 weight loss drugs. 
Stephens also highlighted the company's disciplined M&amp;A strategy to help with long-term growth. Evercore ISI Group also recently<a href="https://www.benzinga.com/quote/TMO/analyst-ratings"> raised the price target</a> on the stock from $605 to $630 while maintaining an Outperform rating.
The company is set to report third-quarter financial results on Oct. 23. Thermo Fisher has beaten analyst estimates for earnings per share in seven of the past 10 quarters and beaten revenue estimates from analysts in seven of the past 10 quarters.
Thermo Fisher shares are up 0.5% over the past five days and up around 10% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209.png" alt="" class="wp-image-591830" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/11133322/Screenshot-209-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 13</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/09/40962321/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 20</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/41072065/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 27</a></li>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">October 4</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a" target="_blank" rel="noreferrer noopener">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a></li>
</ul>

Exclusives

Tech

MPWR

MSTR

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

RBC Capital analyst Kenneth Lee maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Outperform and raises the price target from $150 to $170.

ARES

RBC Capital Maintains Outperform on Ares Management, Raises Price Target to $170

In a report released on September 3, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a price ...

Valneva (0OB3) Receives a Buy from Kepler Capital

Valneva (VALN) has released an update. Valneva SE is initiating a private placement of approximately 60 million euros worth of new ordinary shares ...

Valneva Launches 60M Euro Share Placement for Vaccine Development

Kepler Capital analyst Justine Telliez maintained a Buy rating on Valneva (0OB3 – Research Report) on September 13 and set a price target of €9.00....

Kepler Capital  Sticks to Their Buy Rating for Valneva (0OB3)

Valneva (VALN) has released an update. Valneva SE, a specialty vaccine company, has announced submissions to extend the label of its chikungunya va...

Valneva Seeks to Expand Chikungunya Vaccine Use

Kepler Capital analyst Justine Telliez maintained a Buy rating on Valneva (0OB3 – Research Report) on September 18 and set a price target of €8.10....

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Valneva (VALN – Research Report). The associated price target was lower...

Buy Rating Affirmed for Valneva Amidst Promising Vaccine Development and Financial Prospects

Stifel Nicolaus analyst James Orsborne has reiterated their bullish stance on 0OB3 stock, giving a Buy rating on September 18. James Orsborne has g...

Valneva's Growth Prospects and Market Undervaluation Justify a Buy Rating

Valneva (VALN) has released an update. Valneva SE, a specialty vaccine company, has announced an Investor Day event to be held in New York on Octob...

Valneva Announces Investor Day to Showcase Vaccine Pipeline

Valneva (VALN) has released an update. Valneva SE, a specialty vaccine company, is conducting an investor day in New York City to showcase its Lyme...

Valneva Outlines Future Growth and Vaccine Pipeline

Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Valneva (VALN – Research Report), reducing the price target to $20.00. Edward Wh...

Buy Rating for VALN: Strong Vaccine Pipeline and Financial Upside

VALN

Press Releases

Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ®

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Contracts

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Comments

Valneva

Intérêt court

Valneva (NASDAQ:VALN) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL